ATE85079T1 - Vektoren und verfahren zur expression einer die aktivitaet des menschlichen proteins-c enthaltenden substanz. - Google Patents

Vektoren und verfahren zur expression einer die aktivitaet des menschlichen proteins-c enthaltenden substanz.

Info

Publication number
ATE85079T1
ATE85079T1 AT86300823T AT86300823T ATE85079T1 AT E85079 T1 ATE85079 T1 AT E85079T1 AT 86300823 T AT86300823 T AT 86300823T AT 86300823 T AT86300823 T AT 86300823T AT E85079 T1 ATE85079 T1 AT E85079T1
Authority
AT
Austria
Prior art keywords
protein
activity
expression
produce
vectors
Prior art date
Application number
AT86300823T
Other languages
English (en)
Inventor
Nils Ulrik Bang
Robert John Beckmann
Stanley Richard Jaskunas Jr
Mei-Huei Tsai Lai
Sheila Parks Little
George Louis Long
Robert Frank Santerre
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=24811674&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE85079(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Application granted granted Critical
Publication of ATE85079T1 publication Critical patent/ATE85079T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • C12N9/6424—Serine endopeptidases (3.4.21)
    • C12N9/6464—Protein C (3.4.21.69)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21069—Protein C activated (3.4.21.69)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/832—Bacillus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/848—Escherichia
    • Y10S435/849—Escherichia coli
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/8215—Microorganisms
    • Y10S435/822—Microorganisms using bacteria or actinomycetales
    • Y10S435/886—Streptomyces

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT86300823T 1985-02-08 1986-02-06 Vektoren und verfahren zur expression einer die aktivitaet des menschlichen proteins-c enthaltenden substanz. ATE85079T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US06/699,967 US4775624A (en) 1985-02-08 1985-02-08 Vectors and compounds for expression of human protein C
EP86300823A EP0191606B2 (de) 1985-02-08 1986-02-06 Vektoren und Verfahren zur Expression einer die Aktivität des menschlichen Proteins-C enthaltenden Substanz

Publications (1)

Publication Number Publication Date
ATE85079T1 true ATE85079T1 (de) 1993-02-15

Family

ID=24811674

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86300823T ATE85079T1 (de) 1985-02-08 1986-02-06 Vektoren und verfahren zur expression einer die aktivitaet des menschlichen proteins-c enthaltenden substanz.

Country Status (21)

Country Link
US (2) US4775624A (de)
EP (1) EP0191606B2 (de)
JP (6) JPH0698002B2 (de)
KR (1) KR860006546A (de)
CN (1) CN86100868A (de)
AT (1) ATE85079T1 (de)
AU (1) AU593538B2 (de)
CA (1) CA1341073C (de)
DE (2) DE3687584T4 (de)
DK (2) DK55486D0 (de)
ES (2) ES8704206A1 (de)
GR (1) GR860334B (de)
HU (1) HU211032B (de)
IE (1) IE59423B1 (de)
IL (1) IL77781A (de)
MY (1) MY103018A (de)
NZ (1) NZ215031A (de)
PH (1) PH25396A (de)
PT (1) PT81959B (de)
SG (1) SG50631A1 (de)
ZA (1) ZA86780B (de)

Families Citing this family (103)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
US5981216A (en) * 1985-04-01 1999-11-09 Alusuisse Holdings A.G. Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
JP2584443B2 (ja) * 1985-04-22 1997-02-26 ジエネテイツクス・インスチチユ−ト・インコ−ポレ−テツド 活性化▲ｉ▼▲ｘ▼因子の高収率産生
CA1341228C (en) * 1985-06-27 2001-05-15 Mark J. Murray Expression of protein c
US5516650A (en) * 1985-06-27 1996-05-14 Zymogenetics, Inc. Production of activated protein C
US4959318A (en) * 1985-06-27 1990-09-25 Zymogenetics, Inc. Expression of protein C
US4968626A (en) * 1985-08-15 1990-11-06 Board Of Reagents Of The University Of Washington DNA sequence coding for protein C
USRE38981E1 (en) * 1985-08-15 2006-02-14 Board Of Regents Of The University Of Washington DNA sequence coding for protein C
US5618715A (en) * 1985-12-20 1997-04-08 Oncogen Limited Partnership Oncostatin M and novel compositions having anti-neoplastic activity
GB8607502D0 (en) * 1986-03-26 1986-04-30 Antibioticos Sa Penicillium chrysogenum
IL98886A (en) * 1986-04-09 1992-12-01 Lilly Co Eli Method for producing a functional polypeptide in a eukaryotic cell
US5550036A (en) * 1986-04-09 1996-08-27 Eli Lilly And Company Method for co-amplification of human protein C genes in human cells
JPS63105675A (ja) * 1986-10-23 1988-05-10 Green Cross Corp:The ヒトウロキナ−ゼの製造方法
WO1988005466A2 (en) * 1987-01-15 1988-07-28 Codon Tandem gene eukaryotic expression vectors
EP0380508A4 (en) * 1987-05-18 1991-04-03 Integrated Genetics, Inc. Improved protein c molecules and method for making and activating same
DK260987D0 (da) * 1987-05-22 1987-05-22 Nordisk Gentofte Fremgangsmaade til fremstilling af et humant protein samt dna-sekvens til anvendelse ved udoevelse af fremgangsmaaden
JPS6445398A (en) * 1987-08-13 1989-02-17 Kowa Co Antithrombin-binding substance monoclonal antibody, hybridoma producing said antibody and method for purifying and measuring thrombin-binding substance utilizing said monoclonal antibody
US5084274A (en) * 1987-11-17 1992-01-28 Scripps Clinic And Research Foundation Inhibition of arterial thrombotic occlusion or thromboembolism
IL87171A (en) * 1987-11-23 1995-08-31 Monsanto Co cDNA of human tissue factor inhibitor
US4992373A (en) * 1987-12-04 1991-02-12 Eli Lilly And Company Vectors and compounds for direct expression of activated human protein C
ZA889497B (en) * 1987-12-28 1990-08-29 Lilly Co Eli Vectors and compounds for expression of zymogen forms of human protein c
US5196322A (en) * 1987-12-28 1993-03-23 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
US5009889A (en) * 1987-12-31 1991-04-23 Oklahoma Medical Research Foundation Treatment of dysfunctional vascular endothelium using activated protein C
JPH01285196A (ja) * 1988-05-11 1989-11-16 Chisso Corp 発光蛋白エクオリンの製造法
GB8819607D0 (en) * 1988-08-17 1988-09-21 Wellcome Found Novel combination
CA1332049C (en) * 1988-10-07 1994-09-20 Eli Lilly And Company Eukaryotic expression
US5047335A (en) * 1988-12-21 1991-09-10 The Regents Of The University Of Calif. Process for controlling intracellular glycosylation of proteins
US6423313B1 (en) * 1988-12-30 2002-07-23 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5147638A (en) * 1988-12-30 1992-09-15 Oklahoma Medical Research Foundation Inhibition of tumor growth by blockade of the protein C system
US5120537A (en) * 1989-06-14 1992-06-09 Oklahoma Medical Research Foundation Factor xa based anticoagulant compositions
SE464135B (sv) * 1989-07-14 1991-03-11 Kabivitrum Ab Foerfarande foer bestaemning av funktionell aktivitet av fritt protein s eller protein c i ett plasmaprov
US5358932A (en) * 1989-12-29 1994-10-25 Zymogenetics, Inc. Hybrid protein C
US5225537A (en) * 1989-12-29 1993-07-06 Zymogenetics, Inc. Methods for producing hybrid phospholipid-binding proteins
JP3270462B2 (ja) * 1989-12-29 2002-04-02 ザイモジェネティクス，インコーポレイティド ハイブリッドプロテインｃ
JP3330932B2 (ja) * 1990-01-29 2002-10-07 ノボ ノルディスク ヘルス ケア アクチェンゲゼルシャフト 抗凝固剤タンパク質
IL97312A (en) 1990-02-23 1999-01-26 Lilly Co Eli A method of generating a polypeptide in an eukaryotic vector AND recombinant surrogate cell containing an enhanced transcriptional control unit based on the primary late adenovirus coefficient
US5270178A (en) * 1990-02-23 1993-12-14 Eli Lilly And Company Vectors and compounds for expression of zymogen forms of human protein C
IL97311A0 (en) * 1990-02-23 1992-05-25 Lilly Co Eli Vectors and compounds for expression of glycosylation mutants of human protein c
US5571786A (en) * 1990-08-16 1996-11-05 Immuno Aktiengesellschaft Use of protein C or the activation peptide of protein C for preparing a pharmaceutical preparation
US6262336B1 (en) 1991-01-11 2001-07-17 American Red Cross Expression of a heterologous protein C in mammary tissue of transgenic animals using a long whey acidic protein promoter
ATE211177T1 (de) * 1991-01-11 2002-01-15 American Nat Red Cross Expression von aktivem menschlichem protein c im milchdrüsengewebe transgener tiere
US5831141A (en) * 1991-01-11 1998-11-03 United States Of America As Represented By The Department Of Health And Human Services Expression of a heterologous polypeptide in mammary tissue of transgenic non-human mammals using a long whey acidic protein promoter
US5965789A (en) * 1991-01-11 1999-10-12 American Red Cross Engineering protein posttranslational modification by PACE/furin in transgenic non-human mammals
US5861374A (en) * 1991-02-28 1999-01-19 Novo Nordisk A/S Modified Factor VII
US5788965A (en) * 1991-02-28 1998-08-04 Novo Nordisk A/S Modified factor VII
US5817788A (en) * 1991-02-28 1998-10-06 Zymogenetics, Inc. Modified factor VII
US5997864A (en) 1995-06-07 1999-12-07 Novo Nordisk A/S Modified factor VII
US5833982A (en) 1991-02-28 1998-11-10 Zymogenetics, Inc. Modified factor VII
AT397615B (de) * 1991-05-14 1994-05-25 Immuno Ag Arzneimittel enthaltend protein c
US6039944A (en) * 1992-02-28 2000-03-21 Zymogenetics, Inc. Modified Factor VII
MY110664A (en) * 1992-05-21 1999-01-30 Lilly Co Eli Protein c derivatives
DE4320294A1 (de) * 1993-06-18 1994-12-22 Immuno Ag Verwendung von humanem Protein C zur Verhinderung und Behandlung von Thrombozytenablagerungen
US7060484B1 (en) 1993-11-12 2006-06-13 Gilead Sciences, Inc. Polypeptides and coagulation therapy
ATE293168T1 (de) * 1993-11-12 2005-04-15 Gilead Sciences Inc Thrombin mutanten
US5618714A (en) * 1993-12-15 1997-04-08 Eli Lilly And Company Methods for producing protein C
WO1995024929A2 (en) * 1994-03-15 1995-09-21 Brown University Research Foundation Polymeric gene delivery system
AU2467395A (en) * 1994-05-04 1995-11-29 Board Of Trustees Of The University Of Arkansas, The Novel ophthalmologic uses of protein c
US6017697A (en) 1994-11-14 2000-01-25 Eli Lilly And Company Excitatory amino acid receptor protein and related nucleic acid compounds
AT403167B (de) * 1994-11-14 1997-11-25 Immuno Ag Selektion und expression von fremdproteinen mittels eines selektions-amplifikations-systems
US6211142B1 (en) * 1995-03-10 2001-04-03 Genentech, Inc. Compositions comprising gas6 polypeptides and articles of manufacture comprising the same
ATE491029T1 (de) 1996-10-16 2010-12-15 Zymogenetics Inc Fibroblasten-wachstumsfaktoren-homologe
AU730133B2 (en) * 1996-11-08 2001-02-22 Oklahoma Medical Research Foundation Modified protein C and methods of use thereof
US20060127387A1 (en) * 1997-04-22 2006-06-15 Zikria Bashir A Compositions based on polysaccharides and protein C and methods of using the same for preventing and treating sepsis and other conditions
US6630137B1 (en) * 1997-04-28 2003-10-07 Eli Lilly And Company Activated protein C formulations
ZA983496B (en) * 1997-04-28 1999-10-25 Lilly Co Eli Methods for processing activated protein C.
BR9809932A (pt) * 1997-06-05 2000-08-01 Lilly Co Eli Métodos para tratamento de distúrbios trombóticos
HUP0001237A3 (en) * 1997-10-20 2002-01-28 Lilly Co Eli Methods for treating vascular disorders
US6815533B1 (en) 1998-07-31 2004-11-09 Eli Lilly And Company Cryogranulation of activated protein C
CN1324244A (zh) 1998-10-22 2001-11-28 伊莱利利公司 治疗脓毒症的方法
DE69930419T2 (de) 1998-11-13 2006-09-07 Eli Lilly And Co., Indianapolis Verwendung von menschliche protein c zur herstellung eines arzneimittels zur behandlung von heparininduzierter thrombozytopenie
ATE235915T1 (de) 1998-11-20 2003-04-15 Lilly Co Eli Behandlung von hämorrhagischem virusfieber mit protein c
BR9915572A (pt) 1998-11-23 2001-08-14 Lilly Co Eli Processo de tratamento de doença de célula falciforme e talassemia
EP1237917A2 (de) * 1999-11-19 2002-09-11 Eli Lilly And Company Derivate aus protein c
US7204981B2 (en) * 2000-03-28 2007-04-17 Eli Lilly And Company Methods of treating diseases with activated protein C
EP1289543A2 (de) 2000-05-24 2003-03-12 Eli Lilly And Company Formulierungen und verfahren zur behandlung von hyperkoagulablen zustäanden
MXPA03003388A (es) * 2000-10-18 2005-03-07 Maxygen Aps Moleculas de proteina c o similares a las de proteina c activadas.
US6933367B2 (en) 2000-10-18 2005-08-23 Maxygen Aps Protein C or activated protein C-like molecules
WO2002085117A1 (en) * 2001-04-24 2002-10-31 Eisai Co., Ltd. Methods and compositions for preventing and treating septic shock and endotoxemia
JP2004535461A (ja) * 2001-07-19 2004-11-25 ディーエムアイ バイオサイエンシズ インコーポレイテッド プロテインｃの不活性化を抑制するための銅キレート剤の使用
EP1453529A4 (de) 2001-09-19 2007-09-26 Oklahoma Med Res Found Behandlung von sepsis mit tafi
US20030073636A1 (en) * 2001-09-19 2003-04-17 Oklahoma Medical Research Foundation Method of treating diabetes
US7308303B2 (en) * 2001-11-01 2007-12-11 Advanced Bionics Corporation Thrombolysis and chronic anticoagulation therapy
US20050143283A1 (en) * 2002-03-08 2005-06-30 Eli Lilly And Company Activated protein c formulations
WO2004056309A2 (en) 2002-12-05 2004-07-08 Socratech L.L.C. Neuroprotective activity of activated protein c is independent of its anticoagulant activity
WO2004060395A1 (ja) 2002-12-27 2004-07-22 Juridical Foundation The Chemo-Sero-Therapeutic Research Institute 悪性腫瘍治療における生命予後の改善剤
US20070142272A1 (en) * 2003-01-24 2007-06-21 Zlokovic Berislav V Neuroprotective activity of activated protein c independent of its anticoagulant activity
US9192657B2 (en) * 2003-07-08 2015-11-24 The Scripps Research Institute Activated protein C variants with normal cytoprotective activity but reduced anticoagulant activity
EP1651252B1 (de) * 2003-07-08 2014-11-26 The Scripps Research Institute Aktivierte protein c varianten mit normaler zytoprotektiver aktivität aber verringerter gerinnungshemmender aktivität
EP2305821A3 (de) 2004-02-13 2011-04-13 Novozymes A/S Proteasevarianten
JP2008507561A (ja) * 2004-07-23 2008-03-13 ザ ユニバーシティ オブ ロチェスター 活性化プロテインｃによる、脳内のプラスミノゲン活性化因子の不都合な作用の阻害
US20090148458A1 (en) * 2005-06-23 2009-06-11 The University Of British Columbia Coagulation factor iii polymorphisms associated with prediction of subject outcome and response to therapy
BRPI0613137A2 (pt) * 2005-06-24 2010-12-21 Drugrecure Aps administração em vias aéreas de proteìna c ativada em condições inflamatórias afetando o trato respiratório
EP2041338A4 (de) * 2006-06-09 2009-09-30 Univ British Columbia Interferon-gamma-polymorphismen als indikatoren des patientenergebnisses bei schwerkranken patienten
WO2008048646A1 (en) * 2006-10-18 2008-04-24 Socratech L.L.C. Use of human protein c with altered glycosylation and sialic acid content as a medicament
US20100284997A1 (en) * 2006-10-31 2010-11-11 Griffin John H Dosing regimen of activated protein c and variants having reduced anticoagulant activity
CA2712057A1 (en) * 2008-01-15 2009-07-23 The University Of British Columbia Protein c rs2069915 as a response predictor to survival and administration of activated protein c or protein c-like compound
RU2469093C2 (ru) * 2008-12-19 2012-12-10 Общество с ограниченной ответственностью "Лаборатория медицинской биотехнологии" (ООО "ЛМБТ") ЭКСПРЕССИОННАЯ ПЛАЗМИДНАЯ ДНК pCID-PROC, КОДИРУЮЩАЯ ПРОТЕИН С ЧЕЛОВЕКА, И КЛЕТОЧНАЯ ЛИНИЯ DG-CID-PROC-1, ПРОДУЦИРУЮЩАЯ РЕКОМБИНАНТНЫЙ ПРОТЕИН С ЧЕЛОВЕКА
WO2012068519A2 (en) 2010-11-19 2012-05-24 Sirius Genomics Inc. Markers associated with response to activated protein c administration, and uses thereof
ES2676422T3 (es) 2012-07-04 2018-07-19 Zz Biotech Llc Proteína C activada para su uso en el tratamiento de trastornos inflamatorios de la piel
ES2890675T3 (es) 2014-04-16 2022-01-21 Zz Biotech Llc APC para uso en el tratamiento de cicatrices cutáneas anormales
PT3131572T (pt) 2014-04-16 2021-09-24 Zz Biotech Llc Análogo de apc para utilização em cicatrização de feridas
EP4332231A3 (de) 2014-04-29 2024-05-29 Novartis AG Neuartige wirbeltierzellen und verfahren zur rekombinanten expression eines polypeptids von interesse
WO2023119230A1 (en) 2021-12-22 2023-06-29 L'oreal Coagulation pathway and nicotinamide-adenine dinucleotide pathway modulating compositions and methods of their use

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4438032A (en) * 1981-01-30 1984-03-20 The Regents Of The University Of California Unique T-lymphocyte line and products derived therefrom
US4382028A (en) * 1982-07-19 1983-05-03 Monsanto Company Separation of plasma proteins from cell culture systems
AU572125B2 (en) * 1983-03-17 1988-05-05 Mabco Limited Monoclonal antibodies with specificity for crosslinked fibrin and their diagnotic uses
US4775624A (en) * 1985-02-08 1988-10-04 Eli Lilly And Company Vectors and compounds for expression of human protein C
JP2584443B2 (ja) * 1985-04-22 1997-02-26 ジエネテイツクス・インスチチユ−ト・インコ−ポレ−テツド 活性化▲ｉ▼▲ｘ▼因子の高収率産生
AU603768B2 (en) * 1985-07-04 1990-11-29 Kanegafuchi Kagaku Kogyo Kabushiki Kaisha Lymphotoxin dna, lymphotoxin expression vector, lymphotoxin resistant cell, transformant with lymphotoxin expression vector and process for preparing lymphotoxin

Also Published As

Publication number Publication date
JPH0759190B2 (ja) 1995-06-28
HUT40168A (en) 1986-11-28
DE3687584T3 (de) 2001-05-03
ZA86780B (en) 1987-09-30
EP0191606B1 (de) 1993-01-27
PT81959A (en) 1986-03-01
ES8704206A1 (es) 1987-03-16
JPS61205487A (ja) 1986-09-11
DK55486D0 (da) 1986-02-05
DE3687584T2 (de) 1993-05-27
JPH10327876A (ja) 1998-12-15
EP0191606A2 (de) 1986-08-20
IL77781A (en) 1991-08-16
DK55086D0 (da) 1986-02-05
PT81959B (pt) 1988-07-01
JPH09273A (ja) 1997-01-07
NZ215031A (en) 1988-02-29
EP0191606A3 (en) 1987-01-21
SG50631A1 (en) 1998-07-20
JP2854283B2 (ja) 1999-02-03
IE59423B1 (en) 1994-02-23
AU5325686A (en) 1986-08-14
MY103018A (en) 1993-04-30
JPH06189782A (ja) 1994-07-12
GR860334B (en) 1986-06-05
JPH08317794A (ja) 1996-12-03
HU211032B (en) 1995-09-28
ES8707764A1 (es) 1987-08-16
ES551761A0 (es) 1987-03-16
EP0191606B2 (de) 2001-01-24
JPH0698002B2 (ja) 1994-12-07
JP2992002B2 (ja) 1999-12-20
PH25396A (en) 1991-06-03
DK55086A (da) 1986-08-09
JP2873153B2 (ja) 1999-03-24
AU593538B2 (en) 1990-02-15
DE3687584D1 (de) 1993-03-11
US4775624A (en) 1988-10-04
KR860006546A (ko) 1986-09-13
CN86100868A (zh) 1986-09-24
JP2854282B2 (ja) 1999-02-03
JPH06220092A (ja) 1994-08-09
DE3687584T4 (de) 2001-07-26
CA1341073C (en) 2000-08-08
IE860328L (en) 1986-08-08
ES557100A0 (es) 1987-08-16
US5151268A (en) 1992-09-29

Similar Documents

Publication Publication Date Title
DE3687584D1 (de) Vektoren und verfahren zur expression einer die aktivitaet des menschlichen proteins-c enthaltenden substanz.
ES2005073A6 (es) Procedimiento para preparar benzamidas y bencenoacetamidas
DE69033509D1 (de) Laserverfahren zur Behandlung von Mikrokapseln oder Teilchen
DE69034018D1 (de) Kombinierte verwendung von hyaluronsäure und therapeutischen wirkstoffen zur verbesserung des therapeutischen effekts
BR9408025A (pt) Compostos de peptidila e seu uso terapêutico como inibidores de metaloproteinases
BR8302318A (pt) Ativador de plasminogenio de tecido humano,seguencia de dna,vetor de expressao replicavel,plasmideo,microorganismo ou cultura celulor,composicao,uso do dito ativador,processo de expressao,e processo para produzir t pa humano
ES2038609T3 (es) 4,5-dihidroisoxazol, 3,5 disustituido como inhibidores de transglutaminasa.
DE3878627D1 (de) Zusammensetzung zur oberflaechenbehandlung von kautschuk.
ES2002398A6 (es) Procedimiento para preparar nuevas enolamidas
DE3686622D1 (de) Verwendung von dioxopiperidin-derivaten zur behandlung von anxietas, zur herabsetzung von chronischen abnormal hohen gehirn-spiegeln serotonins oder 5-hydroxy-indolessigsaeure und zur behandlung von bakteriellen oder viralen infektionen.
DE3884895D1 (de) Verwendung von Bezafibrat zur Behandlung von Diabetes.
DE3772464D1 (de) Verwendung von zinksalz und b6-vitamin-mischungen zur begrenzung des alopezie- und/oder seborrhoeprozesses.
ES2061558T3 (es) Sondas de hibridacion de acidos nucleicos de papilomavirus humanos y metodos para su empleo.
IT8620561A1 (it) Procedimento e dispositivo per il trattamento di prodotti di uovo, o relativi composti, per prolungare la durata dei prodotti medesimi
ATE86611T1 (de) Topische vorstufen von arzneimitteln zur behandlung von akne und hautkrankheiten.
DK149787D0 (da) Oxazepamholdigt farmaceutisk middel, fremgangsmaade til fremstilling deraf samt dets anvendelse
AT380493B (de) Mittel zur chemischen oberflaechenbehandlung von metallen
DE3684825D1 (de) Verwendung von n-(1-allyl-2-pyrrolidinylmethyl)-2-methoxy-4-amino-5-methylsulfamoylbenzamid zur behandlung der parkinson-krankheit.
DE3881377D1 (de) Mittel zur prophylaxe und behandlung von thrombocytopenie.
UA20171A1 (uk) Спосіб визhачеhhя активhості протеїhа 3 або їх іhгібіторів в біологічhих рідиhах
ATE44481T1 (de) Vorrichtung zur behandlung von werkstuecken.
IT8523117A0 (it) Procedimento di concia di pelli conservate mediante salatura, ed impianto per attuarlo.
IT8564503A0 (it) Procedimento per il trattamento dei sottoprodotti della macellazione edi conceria

Legal Events

Date Code Title Description
EELA Cancelled due to lapse of time